Log in to search using one of your social media accounts:

 

BRCA Breast Cancer Gene Doesn't Affect Survival

BRCA mutations are inherited and increase the risk of breast and ovarian cancers. Between 45 percent and 90 percent of women with a BRCA mutation develop breast cancer, compared with about 12.5 percent of women in the general population.
Source: WebMD Health - Category: Consumer Health News Source Type: news

Related Links:

Conclusions: Our results suggest a link between BRCA mutation, accelerated ovarian aging and systemic aging-related pathophysiology. PMID: 29662617 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
In this study, we examined the impact patient travel burden has on administration of prophylactic G-CSFs and the subsequent impact on FN incidence. METHODS: Medicare claims data were used to identify a cohort of beneficiaries age 65+ with non-myeloid cancers at high risk for FN between January 2012 and December 2014. Driving distance and time were calculated from patient residence ZIP code to the location of G-CSF and/or chemotherapy administration. Regression models were used to estimate the odds of G-CSF prophylaxis relative to patient driving distance and time, and odds of FN incidence relative to timing of G-CSF ad...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
ConclusionOur findings suggest that promoting a healthy lifestyle may aid in the primary prevention of postmenopausal  breast and endometrial cancers.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
Though LHRH agonists may be the preferred method of ovarian function suppression, ovarian ablation is a viable option for select premenopausal breast cancer patients.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Breast Cancer Oncology Journal Source Type: news
Reversible ovarian function suppression using LHRH agonists is the preferred first treatment for most premenopausal breast cancer patients.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Breast Cancer Oncology Journal Source Type: news
Publication date: Available online 5 April 2018 Source:The Kaohsiung Journal of Medical Sciences Author(s): Miriam de La Puente-Yagüe, Maria A. Cuadrado-Cenzual, María J. Ciudad-Cabañas, Marta Hernández-Cabria, Luis Collado-Yurrita Vitamin D is a fat soluble vitamin that plays a role in calcium and phosphorus homeostasis. Recently, extensive research on its extraskeletal actions has linked vitamin D deficiency to an increased risk of infection, diabetes mellitus types 1 and 2, cardiovascular disease, obesity, asthma, inflammatory bowel disease, colon, breast, prostate and ovarian cancer and some ...
Source: The Kaohsiung Journal of Medical Sciences - Category: Universities & Medical Training Source Type: research
Authors: Wang Y, Lan GB, Peng FH, Xie XB Abstract Renal transplantation is associated with an increased risk of cancers at multiple sites; however, the relationships between increased cancer risk and participant characteristics remain unclear. We searched PubMed, Embase, and the Cochrane Library to identify prospective observational studies performed up to July 2017. Totally 11 prospective studies reported data on 79,988 renal transplant recipients were included. Renal transplant recipients were found to display a higher risk of all cancers (standard incidence ratio [SIR]: 2.89; 95% CI: 2.13-3.91; P
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
AbstractA challenge in counseling patients with a family history suggesting a hereditary cancer syndrome is deciding which genetic tests or panels to order. In this article, we discuss the identification of multiple familial mutations through genetic counseling and panel testing. For patients meeting National Comprehensive Cancer Network criteria for clinical genetic testing, providers should consider expanded panels to provide a more complete assessment of one's genetic risk. The continued use of expanded panel testing in the clinical setting will help inform optimal management of cancer patients, as well as the managemen...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Precision Medicine, Cancer Diagnostics and Molecular Pathology Precision Medicine Clinic: Molecular Tumor Board Source Type: research
Opinion statementThe single agent activity of PARP inhibitors (PARPi) in germlineBRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer. The US Food and Drug Administration has approved three PARPi (olaparib, rucaparib, and niraparib) so far to treat certain ovarian cancers, including those with gBRCAm and olaparib for treatment of gBRCAm breast cancers. Several PARPi are now under clinical development for breast cancer in the various treatment settings. Recently, two phase III trials of olaparib (OlympiaD) and talazoparib (EMBRACA) demonstrated 3-month progr...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Our data demonstrated that GDF15 promoted the proliferation of cervical cancer cells via the up-regulation of CyclinD1 and CyclinE1 and the down-regulation of p21 through both the PI3K/AKT and MAPK/ERK signaling pathways in a complex with ErbB2. PMID: 29636108 [PubMed - in process]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: J Exp Clin Cancer Res Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | Health | Ovarian Cancer | Ovaries | Women